{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70754"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/mazdutide\/","title":{"rendered":"Mazdutida"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es Mazdutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Mazdutida<\/strong> (developmental codes IBI362 \/ LY3305677) is a long-acting dual GLP-1 and glucagon receptor co-agonist peptide developed by Innovent Biologics (in-licensed from Eli Lilly). It is the first dual GLP-1\/glucagon agonist to reach Phase 3 trials in obesity and type 2 diabetes, with the glucagon component adding an energy-expenditure mechanism beyond what GLP-1-only and GLP-1\/GIP-dual peptides produce. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2376247-09-1 (mazdutide; com\u00fanmente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Coagonista dual de larga duraci\u00f3n de los receptores de GLP-1 \/ glucag\u00f3n (p\u00e9ptido sint\u00e9tico acilado; Innovent IBI362 \/ Eli Lilly LY3305677; estructura derivada de la oxintomodulina)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4.865 Da (con acilaci\u00f3n de \u00e1cido graso; forma madura publicada)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estructura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00e9ptido sint\u00e9tico basado en la estructura natural de la oxintomodulina (el agonista dual end\u00f3geno de GLP-1\/glucag\u00f3n), con sustituciones dise\u00f1adas para resistencia a la DPP-4 y un anclaje de \u00e1cido diacilgraso unido a un residuo de lisina mediante un enlazador \u03b3-Glu. La cadena acil impulsa la uni\u00f3n reversible a la alb\u00famina s\u00e9rica, lo que produce la semivida prolongada semanal.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos. Los p\u00e9ptidos acilados pueden disolverse m\u00e1s lentamente \u2014 permita tiempo adicional de equilibraci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es Mazdutide?<\/h2>\n<p><strong>Mazdutida<\/strong> is a long-acting synthetic dual GLP-1 and glucagon receptor co-agonist developed under the developmental codes IBI362 (Innovent Biologics, in-licensed from Eli Lilly LY3305677). It is one of the most advanced compounds in the renewed wave of oxyntomodulin-derived dual-agonist pharmacology \u2014 an approach distinct from both the GLP-1-only programme (semaglutide) and the GLP-1\/GIP dual-agonist programme (tirzepatide). The structural inspiration is oxyntomodulin itself, a 37-amino-acid product of preproglucagon processing in intestinal L-cells that natively activates both the GLP-1 and glucagon receptors. Endogenous oxyntomodulin has very short pharmacokinetics; mazdutide engineers around this with a fatty-acid acyl tether at a lysine residue that drives reversible serum-albumin binding and extends the plasma half-life sufficiently for once-weekly subcutaneous administration in clinical studies. Mazdutide has a mature molecular weight of approximately 4,865\u00a0Da including the acyl modification. The structural scaffold preserves the dual-receptor pharmacology of oxyntomodulin while engineered substitutions confer resistance to DPP-4-mediated proteolytic cleavage that would otherwise produce rapid clearance. Mazdutide is the lead Chinese metabolic peptide programme, with Phase 3 trials (GLORY-1 in obesity, DREAMS-1 and DREAMS-2 in type 2 diabetes) reporting body-weight reductions of approximately 15\u201317% at the highest dose tier over 48 weeks. Outside China, mazdutide is <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major Western regulator. In China, mazdutide has been approved by the NMPA under its initial commercial brand \u2014 making it one of the first dual-agonist incretin peptides to receive regulatory clearance for human use anywhere. For the triple-agonist comparator that adds GIP on top of the same GLP-1\/glucagon combination, see our <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> p\u00e1gina de producto. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Coagonismo Dual del Receptor GLP-1\/Glucag\u00f3n<\/h2>\n<p>Lo que hace que mazdutide sea distintivo mec\u00e1nicamente entre los p\u00e9ptidos metab\u00f3licos de doble agonista actuales es que combina el eje can\u00f3nico de saciedad\/gluc\u00e9mico de GLP-1 con el <strong>eje de gasto energ\u00e9tico del receptor de glucag\u00f3n<\/strong> \u2014 not the GIP receptor axis used by tirzepatide. The dual-receptor profile produces complementary effects across three principal compartments documented in published studies:<\/p>\n<ul>\n<li><strong>Activaci\u00f3n del receptor de GLP-1 \u2014 saciedad, secreci\u00f3n de insulina en las c\u00e9lulas \u03b2, vaciado g\u00e1strico<\/strong> \u2014 Mazdutide activa el receptor GLP-1 en las c\u00e9lulas beta pancre\u00e1ticas (secreci\u00f3n de insulina dependiente de glucosa), neuronas POMC del n\u00facleo arcuado hipotal\u00e1mico (se\u00f1alizaci\u00f3n central de saciedad) y aferentes vagales g\u00e1stricos (vaciamiento g\u00e1strico retardado). Este brazo se superpone con el mecanismo de semaglutide y el componente GLP-1 de tirzepatide y retatrutide.<\/li>\n<li><strong>Activaci\u00f3n del receptor de glucag\u00f3n \u2014 gasto energ\u00e9tico, movilizaci\u00f3n de l\u00edpidos hep\u00e1ticos, activaci\u00f3n del tejido adiposo marr\u00f3n<\/strong> \u2014 The defining feature of mazdutide is the simultaneous activation of the glucagon receptor. Glucagon-receptor agonism increases resting energy expenditure modestly, drives hepatic fatty-acid oxidation and lipid mobilisation from steatotic liver, and contributes to brown adipose tissue activation in published rodent studies. The energy-expenditure component is what distinguishes glucagon-containing multi-agonists (mazdutide, retatrutide, survodutide) from the body-weight effect of GLP-1-only and GLP-1\/GIP-dual peptides \u2014 the latter produce weight loss almost entirely through reduced energy intake, while glucagon-containing agonists add a metabolic-rate component.<\/li>\n<li><strong>Balance de actividad receptora y la \u201cparadoja del glucag\u00f3n\u201d<\/strong> \u2014 El desaf\u00edo farmacol\u00f3gico en el coagonismo del receptor de glucag\u00f3n es lograr un efecto neto beneficioso: el glucag\u00f3n solo aumenta la glucosa al estimular la producci\u00f3n hep\u00e1tica de glucosa, lo que empeorar\u00eda en lugar de mejorar el control gluc\u00e9mico. El componente GLP-1 de mazdutide anula el efecto de glucosa impulsado por el glucag\u00f3n a trav\u00e9s de la acci\u00f3n dominante de reducci\u00f3n de glucosa sobre la insulina y la supresi\u00f3n de glucag\u00f3n en las c\u00e9lulas beta y alfa, mientras que el brazo del glucag\u00f3n preserva los beneficios de movilizaci\u00f3n de l\u00edpidos y gasto energ\u00e9tico. La potencia relativa del receptor GLP-1 al glucag\u00f3n est\u00e1 dise\u00f1ada para favorecer un efecto neto de reducci\u00f3n de glucosa \u2014 una diferencia importante con los agonistas triples como <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> donde GIP tambi\u00e9n contribuye.<\/li>\n<\/ul>\n<p>The fatty-acid acyl tether attached at a lysine residue binds reversibly to circulating serum albumin, producing a plasma depot that extends the effective half-life to support once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route. The mechanism for sustained-release distribution is analogous to semaglutide&#8217;s C18 and tirzepatide&#8217;s C20 fatty-acid systems but with different chain length and linker chemistry tuned to mazdutide&#8217;s dual-receptor pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Mazdutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), food-intake assays, respiratory exchange ratio and resting energy expenditure; canonical dual GLP-1\/glucagon peptide<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 control gluc\u00e9mico, sustitutos de HbA1c, din\u00e1mica de supresi\u00f3n de glucag\u00f3n, sensibilidad a la insulina en modelos de roedores con dieta alta en grasas y db\/db; comparaci\u00f3n directa con agonistas \u00fanicos GLP-1 y comparadores duales GLP-1\/GIP<\/li>\n<li><strong>MASLD\/MASH (enfermedad hep\u00e1tica asociada a disfunci\u00f3n metab\u00f3lica)<\/strong> \u2014 contenido de triglic\u00e9ridos hep\u00e1ticos, ALT\/AST, estadificaci\u00f3n de fibrosis; inter\u00e9s particular debido a la actividad movilizadora de l\u00edpidos del brazo de glucag\u00f3n en el h\u00edgado esteat\u00f3tico<\/li>\n<li><strong>Energy-expenditure studies<\/strong> \u2014 medici\u00f3n del gasto energ\u00e9tico en reposo, activaci\u00f3n del tejido adiposo marr\u00f3n, expresi\u00f3n g\u00e9nica termog\u00e9nica; disecci\u00f3n mec\u00e1nica del componente de tasa metab\u00f3lica impulsado por glucag\u00f3n<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 comparaci\u00f3n directa con el agonista dual alternativo <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (GLP-1\/GIP) y el agonista triple <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (GLP-1\/GIP\/glucagon); receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular and renal studies<\/strong> \u2014 efectos sobre la presi\u00f3n arterial, perfiles lip\u00eddicos, progresi\u00f3n de la aterosclerosis en modelos ApoE<sup>-\/-<\/sup> ; conjunto de datos emergente dada la maduraci\u00f3n de la Fase 3 de mazdutida<\/li>\n<li><strong>Farmacolog\u00eda del eje del glucag\u00f3n<\/strong> \u2014 caracterizaci\u00f3n farmacol\u00f3gica aislada del receptor de glucag\u00f3n, din\u00e1mica de producci\u00f3n hep\u00e1tica de glucosa, equilibrio entre supresi\u00f3n de glucag\u00f3n y agonismo de glucag\u00f3n en mol\u00e9culas agonistas duales<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 comparativa con agonista simple de GLP-1 (<a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a>), agonista dual GLP-1\/GIP (<a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a>), y agonista triple GLP-1\/GIP\/glucag\u00f3n (<a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a>).<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja mazdutida en el panorama de p\u00e9ptidos metab\u00f3licos multiagonistas, consulte <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> como el comparador agonista triple que a\u00f1ade GIP, <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> como el agonista dual alternativo que utiliza GIP en lugar de glucag\u00f3n, <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> como la l\u00ednea base de agonista \u00fanico, y <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> como la alternativa farmacol\u00f3gica combinada en el eje de la amilina. Explore el <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Mazdutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, estudios multicohorte, menor coste por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 4\u20139\u00a0mg weekly, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent single-to-multi-week supplies of clinical-equivalent dosing for in-vivo work. Mazdutide is a comparatively scarce peptide because of structural complexity and active clinical development, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>C\u00f3mo se compara \u2014 Mazdutida vs Retatrutida<\/h2>\n<p>Mazdutida y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> are the two canonical glucagon-receptor-containing multi-agonist metabolic peptides in current studies. They share the GLP-1 + glucagon backbone and differ in whether they also activate the GIP receptor \u2014 Retatrutide does (triple agonist), Mazdutide does not (dual agonist). The comparison is one of the cleanest in current metabolic-peptide pharmacology because the GLP-1 and glucagon arms are shared, isolating the contribution of the GIP component. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucag\u00f3n (dual)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucag\u00f3n (triple)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Andamio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de oxintomodulina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">39 amino\u00e1cidos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal (acilado)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 d\u00edas<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desarrollador \/ origen<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent (IBI362) \/ Eli Lilly (LY3305677)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado regulatorio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprobado en China (NMPA); en investigaci\u00f3n en otros lugares<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">En investigaci\u00f3n (Fase 3)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto sobre el peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317% (GLORY-1 Fase 3, 48 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2, 48 semanas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The principal pharmacological question separating the two is the value of GIP receptor activation on top of GLP-1 + glucagon. Retatrutide&#8217;s Phase 2 body-weight effect is larger, suggesting GIP adds substantial benefit, but the more selective dual-agonist profile of mazdutide produces a potentially cleaner side-effect signal that may matter for long-term tolerability studies. For glucagon-axis-specific pharmacology, mazdutide is the cleaner tool because it isolates the GLP-1 + glucagon combination without the confound of GIP. For maximum-magnitude body-weight studies, the triple-agonist <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> sigue siendo la referencia can\u00f3nica. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para el stock de trabajo a corto plazo. Para el almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El mazdutide liofilizado es estable bajo refrigeraci\u00f3n hasta por 24 meses y a \u221220 \u00b0C hasta por 36 meses. Evite los ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.6\u00a0mL delivers a 4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>ajuste<\/strong> sacuda \u2014 y permita 5\u201310 minutos para una disoluci\u00f3n completa (los p\u00e9ptidos acilados se disuelven m\u00e1s lentamente que los p\u00e9ptidos no modificados m\u00e1s peque\u00f1os). Una soluci\u00f3n correctamente reconstituida debe ser clara e incolora, sin part\u00edculas visibles. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y util\u00edcelo dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Mazdutide used for in studies?<\/h3>\n<p>Mazdutide is used in studies investigating the dual GLP-1 \/ glucagon receptor co-agonist axis, obesity and body-composition regulation, type 2 diabetes preclinical models, MASLD\/MASH liver disease, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), and triple GLP-1\/GIP\/glucagon (retatrutide) compounds. It is the most-cited Chinese-origin metabolic peptide in current literature. The pharmaceutical-grade mazdutide sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia Mazdutide de Semaglutide?<\/h3>\n<p>Semaglutide es un agonista \u00fanico del receptor GLP-1. Mazdutide a\u00f1ade agonismo del receptor de glucag\u00f3n adem\u00e1s del GLP-1. El componente adicional de glucag\u00f3n contribuye a un mecanismo de gasto energ\u00e9tico \u2014 aumento de la tasa metab\u00f3lica en reposo, movilizaci\u00f3n de l\u00edpidos hep\u00e1ticos y activaci\u00f3n del tejido adiposo marr\u00f3n \u2014 que los agonistas \u00fanicos de GLP-1 no producen. En ensayos de Fase 3 comparables, Mazdutide produce un efecto algo mayor en la p\u00e9rdida de peso corporal que Semaglutide solo (15\u201317% vs ~15%), pero la principal diferencia pr\u00e1ctica es la justificaci\u00f3n mec\u00e1nica de la p\u00e9rdida de peso: Semaglutide principalmente a trav\u00e9s de la reducci\u00f3n de la ingesta de alimentos, Mazdutide a trav\u00e9s de la reducci\u00f3n de la ingesta y el aumento del gasto energ\u00e9tico. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia Mazdutide de Tirzepatide?<\/h3>\n<p>Both are dual incretin agonists, but they activate different second receptors. Tirzepatide is GLP-1 + GIP. Mazdutide is GLP-1 + glucagon. The two receptor combinations produce qualitatively different metabolic profiles: GIP (tirzepatide) adds adipocyte lipolysis under fasting conditions and modest effects on energy expenditure; glucagon (mazdutide) adds substantial energy expenditure and hepatic lipid mobilisation. Tirzepatide has the larger Phase 3 dataset and larger body-weight effect; mazdutide has the unique mechanism for MASLD\/MASH studies given the glucagon-driven hepatic lipid component. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia Mazdutide de Retatrutide?<\/h3>\n<p>Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Mazdutide is a dual agonist that shares the GLP-1 + glucagon arms but lacks the GIP component. Retatrutide&#8217;s Phase 2 body-weight effect is larger than mazdutide&#8217;s Phase 3 result, suggesting GIP receptor activation adds substantial benefit on top of GLP-1 + glucagon. For studies isolating the GLP-1 + glucagon combination specifically, mazdutide is the cleaner tool because it avoids the GIP confound; for maximum body-weight effect, retatrutide remains the canonical reference. <\/p>\n<h3>What is the typical Mazdutide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 1.5\u20133\u00a0mg and increasing to maintenance doses of 4\u20139\u00a0mg weekly \u2014 the dose range used in GLORY-1 and DREAMS-1 Phase 3 trials. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.6\u00a0mL equals a 4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>\u00bfEst\u00e1 Mazdutide aprobado por la FDA?<\/h3>\n<p>No. Mazdutide is not FDA-approved in the United States, nor is it EMA- or MHRA-approved. It has been approved by China&#8217;s NMPA for human use (one of the first dual GLP-1\/glucagon agonists to receive any regulatory approval worldwide), but Western regulatory submission is still pending or ongoing as of current literature. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar Mazdutide?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo Mazdutide?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el liofilizado), agite suavemente y deje reposar entre 5 y 10 minutos para una disoluci\u00f3n completa (los p\u00e9ptidos acilados se disuelven m\u00e1s lentamente que los p\u00e9ptidos no modificados m\u00e1s peque\u00f1os). No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Mazdutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 Mazdutide tambi\u00e9n activa el receptor de glucag\u00f3n?<\/h3>\n<p>La inspiraci\u00f3n estructural para Mazdutide es la oxintomodulina, un producto end\u00f3geno de 37 amino\u00e1cidos del procesamiento de preproglucag\u00f3n en las c\u00e9lulas L intestinales que activa de forma natural tanto los receptores de GLP-1 como de glucag\u00f3n. Por lo tanto, la farmacolog\u00eda dual no est\u00e1 dise\u00f1ada \u2014 se hereda del andamio natural de la oxintomodulina. Lo que est\u00e1 dise\u00f1ado es la resistencia a la escisi\u00f3n por DPP-4 y la acilaci\u00f3n de \u00e1cidos grasos que produce una vida media semanal, junto con el ajuste fino de la potencia relativa del receptor GLP-1 frente al glucag\u00f3n para favorecer un efecto neto de reducci\u00f3n de glucosa. <\/p>\n<h3>\u00bfEl componente de glucag\u00f3n causa hiperglucemia?<\/h3>\n<p>This is the classic &#8220;glucagon paradox&#8221; in dual-agonist studies. Glucagon alone raises glucose by stimulating hepatic glucose output, which would worsen rather than improve diabetes. In mazdutide, the GLP-1 component overrides this through dominant glucose-lowering action on insulin and glucagon-suppression at beta- and alpha-cells, while the glucagon arm preserves the lipid-mobilisation and energy-expenditure benefits. Published studies confirms net glucose-lowering despite glucagon receptor activation, demonstrating that the engineered GLP-1-to-glucagon potency ratio achieves the desired balance. <\/p>\n<h3>Does Mazdutide cause side reported effects?<\/h3>\n<p>El hallazgo m\u00e1s consistente es gastrointestinal, similar a otros p\u00e9ptidos del eje GLP-1 \u2014 n\u00e1useas, supresi\u00f3n transitoria del apetito y vaciado g\u00e1strico retardado son dependientes de la dosis y tienden a atenuarse durante 4\u20138 semanas de dosificaci\u00f3n continua a medida que se desarrolla la taquifilaxia del receptor. Los hallazgos relacionados con el componente de glucag\u00f3n incluyen elevaciones modestas en la frecuencia card\u00edaca en reposo y (raramente) efectos transitorios en la presi\u00f3n arterial. Los datos de seguridad a largo plazo contin\u00faan acumul\u00e1ndose a partir de los ensayos de Fase 3 en China y la vigilancia posterior a la aprobaci\u00f3n. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de Mazdutide?<\/h3>\n<p>Mazdutide has a plasma half-life sufficient to support once-weekly subcutaneous dosing in clinical studies, achieved through reversible binding to serum albumin via the fatty-acid acyl tether. The exact half-life is somewhat shorter than semaglutide (~165 hours) but in the same once-weekly dosing regime. The dosing schedule and clinical trial design treat it as a fully once-weekly compound. <\/p>\n<h3>How long does Mazdutide take to show effects in preclinical studies?<\/h3>\n<p>Los efectos farmacodin\u00e1micos agudos sobre la tolerancia a la glucosa y el vaciado g\u00e1strico son detectables a las pocas horas de la primera dosis. Los efectos sobre el peso corporal en modelos de roedores con obesidad inducida por dieta (DIO) suelen ser estad\u00edsticamente significativos despu\u00e9s de 1-2 semanas de administraci\u00f3n semanal y contin\u00faan acumul\u00e1ndose hasta las 8-16 semanas. El efecto m\u00e1ximo sobre la composici\u00f3n corporal se desarrolla durante 16-24 semanas de administraci\u00f3n continua, reflejando la trayectoria de la Fase 3 en humanos del estudio GLORY-1. <\/p>\n<h3>\u00bfPuedo pedir Mazdutide para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Mazdutide a todo el mundo desde nuestra red de distribuci\u00f3n dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente para p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Agonista triple de GLP-1\/GIP\/glucag\u00f3n \u2014 a\u00f1ade GIP al perfil de receptores de mazdutide<\/li>\n<li><a href=\"\/es\/tirzepatide\/\"><strong>Tirzepatida<\/strong><\/a> \u2014 Agonista dual GLP-1\/GIP \u2014 alternativa de agonista dual que utiliza GIP en lugar de glucag\u00f3n<\/li>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Agonista simple de GLP-1 \u2014 comparador de referencia can\u00f3nico<\/li>\n<li><a href=\"\/es\/cagrilintide\/\"><strong>Cagrilintida<\/strong><\/a> \u2014 An\u00e1logo de amilina \u2014 enfoque alternativo de farmacolog\u00eda combinada (CagriSema)<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore el panorama de los p\u00e9ptidos metab\u00f3licos multiagonistas<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados que incluyen <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (agonista triple), <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (doble GLP-1\/GIP), y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> (agonista simple). Gu\u00eda comparativa: <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide \u2014 triple agonista vs dual agonista<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Doble agonista de receptores GLP-1 + glucag\u00f3n<br \/>\n\u2705 Andamio derivado de oxintomodulina (IBI362 \/ LY3305677)<br \/>\n\u2705 A\u00f1ade un mecanismo de gasto energ\u00e9tico m\u00e1s all\u00e1 del GLP-1 solo<br \/>\n\u2705 Aprobado en China; en investigaci\u00f3n en Occidente<br \/>\n\u2705 Dosificaci\u00f3n semanal<\/p>\n<p><strong>Mazdutida<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70965,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6285,5441],"class_list":["post-70754","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mazdutide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70965"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70754"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70754"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70754"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}